Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis

Experimental and Therapeutic Medicine

Volumn 12, Issue 3, 2016, Pages 1693-1704

  Wang, Qiang ^a   Wen, Zhenzhen ^b   Cao, Qian ^b  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Inflammatory bowel disease; Infliximab; Meta analysis; Rheumatoid arthritis; Spondyloarthropathy; Tuberculosis infection

Indexed keywords

INFLIXIMAB; PLACEBO;

ARTICLE; GENETIC HETEROGENEITY; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PUBLICATION; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; TUBERCULOSIS;

EID: 84980319989     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3548     Document Type: Article

References (52)

1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30: 1443-1453, 1993.
2. Scallon BJ, Moore MA, Trinh H, Knight DM and Ghrayeb J: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251-259, 1995.
3. Van Deventer SJ: Tumour necrosis factor and Crohn's disease. Gut 40: 443-448, 1997.
4. Feldmann M, Brennan FM and Maini RN: Rheumatoid arthritis. Cell 85: 307-310, 1996.
5. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M and Dougados M: Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: A retrospective study. Ann Rheum Dis 65: 1631-1634, 2006.
6. Murch SH, Braegger CP, Walker-Smith JA and MacDonald TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709, 1993.
7. Husby G and Williams RC Jr: Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1: 363-371, 1988.
8. Tse SM, Burgos-Vargas R and Laxer RM: Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 52: 2103-2108, 2005.
9. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC and Blom M: Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7: e30275, 2012.
10. Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF and Pontarolo R: A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 28: 1365-1373, 2009.
11. Wiens A, Venson R, Correr CJ, Otuki MF and Pontarolo R: Meta-analysis of the efficacy and safety of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30: 339-353, 2010.
12. Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S and Waljee AK: Systematic review with network meta-analysis: The efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 39: 660-671, 2014.
13. Scheinfeld N: A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15: 280-294, 2004.
14. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW and Bloom BR: Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561-572, 1995.
15. Kindler V, Sappino AP, Grau GE, Piguet PF and Vassalli P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: 731-740, 1989.
16. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, Tsai MM, Flynn JL and Chan J: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun 69: 1847-1855, 2001.
17. Ford AC and Peyrin-Biroulet L: Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: Meta-analysis of randomized controlled trials. Am J Gastroenterol 108: 1268-1276, 2013.
18. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN and Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104, 2001.
19. Wallis RS, Broder MS, Wong JY, Hanson ME and Beenhouwer DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261-1265, 2004.
20. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, et al: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52: 1986-1992, 2005.
21. Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097, 2009.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12, 1996.
23. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P and Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613, 1998.
24. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF and Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029-1035, 1997.
25. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405, 1999.
26. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR and Podolsky DK: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 7: 83-88, 2001.
27. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, et al; ACCENT I Study Group: Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359: 1541-1549, 2002.
28. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, et al: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885, 2004.
29. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476, 2005.
30. Lemann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, et al: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. Gastroenterology 130: 1054-1061, 2006.
31. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395, 2010.
32. Ochsenkuhn T, Sackmann M and Göke B: Infliximab for acute, not steroid-refractory ulcerative colitis: A randomized pilot study. Eur J Gastroenterol Hepatol 16: 1167-1171, 2004.
33. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552-1563, 1998.
34. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343: 1594-1602, 2000.
35. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 50: 3432-3443, 2004.
36. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S and Emery P: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 27-35, 2005.
37. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P and Rahman MU; START Study Group: The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. Arthritis Rheum 54: 1075-1086, 2006.
38. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y and Nagaya I: A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33: 37-44, 2006.
39. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, et al: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67: 1096-1103, 2008.
40. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, et al: Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359: 1187-1193, 2002.
41. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P and Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52: 582-591, 2005.
42. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'connor P, Tan AL, Conaghan PG, Greenstein A and Emery P: Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study. Ann Rheum Dis 64: 1568-1575, 2005.
43. Inman RD and Maksymowych WP; CANDLE Study Group: Adouble-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37: 1203-1210, 2010.
44. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H and Veys EM: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46: 755-765, 2002.
45. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT and Kavanaugh A; IMPACT 2 Trial Investigators: Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 64: 1150-1157, 2005.
46. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, et al: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial. Ann Rheum Dis 66: 498-505, 2007.
47. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, et al: Efficacy and safety of infliximab plus naproxen vs. naproxen alone in patients with early, active axial spondyloarthritis: Results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73: 101-107, 2014.
48. Algood HM, Lin PL and Flynn JL: Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 (Suppl 3): S189-S193, 2005.
49. White DW and Harty JT: Perforin-deficient CD8+ T cells provide immunity to Listeria monocytogenes by a mechanism that is independent of CD95 and IFN-gamma but requires TNF-alpha. J Immunol 160: 898-905, 1998.
50. Zhou P, Miller G and Seder RA: Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol 160: 1359-1368, 1998.
51. Roach DR, Bean AG, Demangel C, France MP, Briscoe H and Britton WJ: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620-4627, 2002.
52. Zumla A, George A, Sharma V, Herbert N and Baroness Masham of Ilton: WHO's 2013 global report on tuberculosis: Successes, threats, and opportunities. Lancet 382: 1765-1767, 2013.